In 2023, it was estimated that almost 10 percent of those aged 65 years and older in the United States had been diagnosed with COPD, emphysema, or chronic bronchitis. This statistic shows the percentage of U.S. adults aged 65 years and older who had ever been told by a doctor or other health professional they had COPD, emphysema, or chronic bronchitis from 2019 to 2023.

In 2023, around *** percent of U.S. adults aged 25 to 44 years had chronic obstructive pulmonary disease (COPD), compared to **** percent of those aged 75 years and older. This statistic shows the percentage of adults in the U.S. with COPD in 2023, by age.

In 2020, around ** percent of all deaths among those in the mining industry in the United States died from chronic obstructive pulmonary disease (COPD). This statistic shows the percentage of deaths in select industries in the United States that were from chronic obstructive pulmonary disease in 2020.

In 2022, around 5.5 percent of men and 6.7 percent of women in the United States aged 18 years and older had chronic obstructive pulmonary disease (COPD). This statistic shows the prevalence of COPD among U.S. adults from 2011 to 2022, by gender.

Background: We aimed to estimate the incidence, mortality, disability-adjusted life years (DALYs) for chronic obstructive pulmonary disease (COPD) in 204 countries and territories. We examined the variations in these trends by country, gender, age group, and sociodemographic index (SDI).Methods: We calculated the estimated annual percentage changes (EAPCs) to assess temporal trends in the age-standardized incidence rate, age-standardized mortality rate, and age-standardized DALYs of COPD from 1990 to 2019.Results: From 1990 to 2019, the COPD incidence and COPD-associated deaths and DALYs increased worldwide by 86%, 30%, and 26%, respectively. From 1990 to 2019, the global age-standardized incidence rate (EAPC, −0.11; 95% confidence interval (CI), −0.25 to 0.04), age-standardized mortality rate (EAPC, −2.10; 95% CI, −2.19 to −2.00), and age-standardized DALYs (EAPC, −1.87; 95% CI, −1.94 to −1.81) of COPD decreased. The age-standardized incidence of COPD increased most in areas with high SDI (EAPC 0.56). The largest increases in the age-standardized incidence rate of COPD were recorded in High-income North America (EAPC, 1.41), Southern Latin America (EAPC, 0.29), and North Africa and the Middle East (EAPC, 0.09). The three countries that recorded the largest increases in COPD incidence from 1990 to 2019 were the United States of America (EAPC, 1.51), Saudi Arabia (EAPC, 1.17), and Oman (EAPC, 1.10).Conclusion: Despite the decreased burden of COPD globally from 1990 to 2019, the age-standardized incidence rate of COPD increased in areas with high SDI, High-income North America, Southern Latin America, North Africa, and the Middle East.

Death rate has been age-adjusted by the 2000 U.S. standard population. Single-year data are only available for Los Angeles County overall, Service Planning Areas, Supervisorial Districts, City of Los Angeles overall, and City of Los Angeles Council Districts.Chronic obstructive pulmonary disease (COPD) refers to a group of diseases, including emphysema and chronic bronchitis, that create airflow blockages in the lungs. Exposure to tobacco smoke is an important risk factor for COPD. Cities and communities can take an active role in curbing tobacco use and reducing COPD by adopting policies to regulate tobacco retail; reducing exposure to secondhand smoke in outdoor public spaces, such as parks, restaurants, or in multi-unit housing; and improving access to tobacco cessation programs and other preventive services.For more information about the Community Health Profiles Data Initiative, please see the initiative homepage.

This statistic shows the percentage of individuals in the U.S. with Chronic Obstructive Pulmonary Disease (COPD) who experienced select symptoms as of 2020. It was found that 88 percent of those with COPD stated they had experienced shortness of breath during everyday activities.

The global Chronic Obstructive Pulmonary Disease (COPD) market size is expected to be valued at US$ 21.58 Billion in 2023. With the increasing alcohol consumption among people, the overall demand for Chronic Obstructive Pulmonary Disease (COPD) is projected to grow at a CAGR of 4.4% between 2023 and 2033, totaling around US$ 33.19 Billion by 2033.

Data Points	Key Statistics
Chronic Obstructive Pulmonary Disease (COPD) Market Value 2023	US$ 21.58 Billion
Chronic Obstructive Pulmonary Disease (COPD) Market Projected Value (2033)	US$ 33.19 Billion
Chronic Obstructive Pulmonary Disease (COPD) Market CAGR (2023 to 2033)	4.4%

Report Scope

Report Attribute	Details
Growth Rate	CAGR of 4.4% from 2023 to 2033
Market Value in 2023	US$ 21.58 Billion
Market Value in 2033	US$ 33.19 Billion
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Drug Class Type Distribution Channel Region
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa (MEA)
Key Countries Profiled	The US Canada Brazil Mexico Germany The UK France Spain Italy China Japan South Korea Malaysia Singapore Australia New Zealand GCC South Africa Israel
Key Companies Profiled	Almirall AstraZeneca Boehringer Ingelheim International GmbH CHIESI Farmaceutici S.p.A. F. Hoffmann-La Roche Ltd. GlaxoSmithKline plc Kyowa Hakko Kirin Mylan N.V. Novartis AG Orion Corporation Sanofi Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.) Teva Pharmaceutical Industries Ltd. Theravance Biopharma Verona Pharmaceuticals

This statistic shows the percentage of individuals in the U.S. with Chronic Obstructive Pulmonary Disease (COPD) who suffered from exacerbation a select number of times in the past year as of 2020. It was found that just 15 percent of those with COPD did not suffer from exacerbation in the past year.

Background: There are limited data on the epidemiology of Non-tuberculous mycobacteria (NTM) infections among patients with COPD, particularly in the veteran population. This study examined the prevalence, incidence, and mortality of pulmonary NTM infections among veterans with COPD population in the United States.Methods: We analyzed nationwide data from Veterans Affairs Hospitals from 2001 to 2015. First, we determined the incidence and prevalence rates and geographic distribution of NTM infections among veterans with COPD and then we evaluated the association between NTM infections with mortality among veterans with COPD. Pulmonary NTM and COPD diagnosis were defined based on charting claims for each condition on ≥2 occasions and ≥30 days apart. COPD diagnoses had to precede diagnosis of NTM. Cox Proportional-Hazards Regression was performed to determine the dependency of survival time of COPD patients with NTM.Results: The incidence and prevalence rates of NTM rose over the study period, with a sharp rise in incidence after 2012. The areas with the highest NTM period prevalence were Puerto Rico (370), followed by Florida (351) and District of Columbia (309) in 100,000 COPD population. Mortality registered for those patients with COPD Patients and NTM infection was 1.43 times higher compared to those that were uninfected.Conclusions: NTM rates have been increasing in veterans with COPD since 2012. NTM infection is associated with increased risk of mortality. This highlights the importance of identifying preventable risk factors associated with NTM infections in subjects with COPD.

The global COPD therapeutics market garnered a market value of US$ 12,144.1 million in 2023 and is expected to accumulate a market value of US$ 20,035.5 million by 2033, registering a CAGR of 5.1% over the forecast period.

Report Attribute	Details
Estimated Base Year Value (2022)	US$ 11,668.2 million
Expected Market Value (2023)	US$ 12,144.1 million
Anticipated Forecast Value (2033)	US$ 20,035.5 million
Projected Growth Rate (2023 to 2033)	5.1% CAGR

How Is the Prevalence of COPD Escalating Demand for COPD Therapeutics in North America?

Region	North America
Market Share % (2022)	36.2%

How are Government Initiatives Augmenting Demand for COPD Therapeutics in Europe?

Region	Europe
Market Share % (2022)	29.8%

Report Scope

Report Attribute	Details
Market Value in 2023	US$ 12,144.1 million
Market Value in 2033	US$ 20,035.5 million
Growth Rate	CAGR of 5.1% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in US$ million and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Component End User Region
Regions Covered	North America Latin America Europe Asia Pacific Middle East and Africa
Key Countries Profiled	The United States Canada Brazil Mexico Germany The United Kingdom France Spain Italy Nordics BENELUX Australia & New Zealand China Japan South Korea India ASEAN GCC South Africa
Key Companies Profiled	Pfizer Inc. Adamis Laboratories Inc. GlaxoSmithKline plc AstraZeneca Merk & Co Novartis AG Mylan N.V. Teva Pharmaceutical Industries
Customization	Available Upon Request

Colorado county-level and state data on rates of hospitalizations among Colorado residents for multiple years as published by the Colorado Environmental Public Health Tracking project. Current years published include 2004-2018.Numerator/denominator informationEvent/numerator data:Hospital discharges, Hospital Discharge Data Set, Colorado Hospital Association.Emergency department discharges, Emergency Department Discharge Data Set, Colorado Hospital Association.Population/denominator data:Midyear resident population estimates. Source: State Demography Office, Colorado Department of Local Affairs.Interpreting the dataWhat these data tell us:These data tell us rates of hospitalizations and emergency department visits among Colorado residents over time and across counties. The rate is the number of hospitalizations or emergency department visits per state or county population in a calendar year.What these data do not tell us:These data do not tell us the number of people who currently have or experience each condition. The data may reflect more severe cases of each condition since people who are hospitalized or admitted to the emergency room often have a more severe illness.Comparisons of these rates of hospitalization and emergency department visits to environmental measures should be done with caution.Elevated rates of hospitalizations and emergency department visits in a geographic area with higher than average environmental exposure do not necessarily indicate that the environmental exposure is causing the higher rate.There may be other factors that lead to increased disease rates within a geographic area. Rates may differ due to factors such as access to medical care which can affect the likelihood of a person being hospitalized for asthma.Calculation methodsCase definition for hospitalizations and emergency department visits occurring:before October 1, 2015 are based on diagnosis codes from the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9CM).on or after October 1, 2015 are based on diagnosis codes from the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10CM).Age-specific rates in each age group and geographic population are calculated:per 10,000 population for asthma, chronic obstructive pulmonary disease (COPD), and heart attack.per 100,000 population for carbon monoxide poisoning and heat-related illness.Age-adjusted rates are calculated:per 10,000 population for asthma, chronic obstructive pulmonary disease, and heart attackper 100,000 population for carbon monoxide poisoning and heat-related illness.Rates are adjusted for differences across age and sex by the direct method using the Year 2000 U.S. Standard Population.Limitations of the dataThe hospital and emergency department visits datasets do not include all cases. Those who do not receive medical care, receive medical treatment in outpatient settings (other than emergency department), or die without being admitted to a hospital are not included in these datasets. Differences in rates by year or county may reflect differences or changes in medical coding or billing for hospitalizations and emergency department visits, or changes in access to medical care. Although exact duplicate records are excluded, the measures are based upon events, not individuals. If the same person is admitted to the hospital or emergency department multiple times for the same condition in the same year, these events would be counted as separate events, even though it was the same person. If people are being counted more than once, the reported rate may be higher than the true rate. Reporting rates at the state and county level is a broad measure. This means the data will not show the true disease burden at a more local level, such as the neighborhood. These data are not geographically specific enough to be linked with many types of environmental exposure, which may vary across the county.Data not includedThese data do not include hospital or emergency department discharges from Federal facilities in Colorado, such as U.S. Department of Veterans Affairs Medical Centers.

In 2023, around two percent of Hispanics in the United States had chronic obstructive pulmonary disease (COPD), compared to 4.4 percent of white, non-Hispanics. This statistic shows the percentage of adults in the U.S. with COPD in 2023, by race and ethnicity.

As of 2022, around **** million adults in the United States were current cigarette smokers. Although this figure is still high, it is significantly lower compared to previous years. For example, in 2011, there were almost ** million smokers in the United States. Smoking demographics in the U.S. Although smoking in the U.S. has decreased greatly over the past few decades, it is still more common among certain demographics than others. For example, men are more likely to be current cigarette smokers than women, with ** percent of men smoking in 2021, compared to ** percent of women. Furthermore, non-Hispanic whites and non-Hispanic Blacks smoke at higher rates than Hispanics and non-Hispanic Asians, with almost ** percent of non-Hispanic whites smoking in 2022, compared to just under **** percent of non-Hispanic Asians. Certain regions and states also have a higher prevalence of smoking than others, with around ** percent of adults in West Virginia considered current smokers, compared to just *** percent in Utah. The health impacts of smoking The decrease in smoking rates in the United States over the past decades is due to many factors, including policies and regulations limiting cigarette advertising, promotion, and sales, price increases for cigarettes, and widespread awareness among the public of the dangers of smoking. According to the CDC, those who smoke are *** to **** times more likely to develop coronary heart disease and stroke and around ** times more likely to develop lung cancer than nonsmokers. In fact, it is estimated that around ** percent of lung cancer deaths in the United States can be attributed to cigarette smoking, as well as ** percent of larynx cancer deaths. Cigarette smokers are also much more likely to develop chronic obstructive pulmonary disease (COPD), with around ** percent of current smokers in the U.S. living with COPD in 2021, compared to just ***** percent of those who had never smoked.

Excel workbook of age-standardised baseline mortality rates (BMRs) for each US county by race and ethnicity used for calculating racial-ethnic disparities in health burdens for air pollution from the major oil and gas lifecycle stages in the United States.The workbook includes 3 sheets:BMRs for all-cause mortality in 25+ years population for calculating premature mortality from exposure to fine particular matter (PM2.5).BMRs for all-cause mortality in 65+ years population for calculating premature mortality from exposure to nitrogen dioxide (NO2), andBMRs for all-ages chronic obstructive pulmonary disease (COPD) mortality from exposure to ozone air pollution.Raw BMRs from the US US Centers for Disease Control and Prevention Wide-ranging ONline Data for Epidemiologic Research (CDC WONDER) are processed to gap fill data not reported at the county level. This data gap filling is detailed in Vohra et al. (2025) Science Advances, "The health burden and racial-ethnic disparities of air pollution from the major oil and gas lifecycle stages in the United States", doi:10.1126/sciadv.adu2241.

The Asthma COPD Drugs Market is a dynamic sector encompassing a wide array of products designed to manage and treat asthma and chronic obstructive pulmonary disease (COPD). These products are categorized primarily by their mechanism of action and usage patterns, offering tailored therapeutic options for patients with varying disease severities.Long-Term Asthma Control Medications: These medications are foundational in managing asthma and preventing exacerbations. They work to reduce airway inflammation and improve lung function. Subcategories include: Combination Drugs: Offer the convenience and efficacy of multiple medications—often inhaled corticosteroids and long-acting bronchodilators—in a single inhaler, improving adherence and simplifying treatment regimens. Inhaled Corticosteroids (ICS): These are cornerstone therapies that effectively reduce airway inflammation, a key driver of asthma symptoms. They are usually administered daily to maintain long-term control. Long-acting Beta2-Agonists (LABAs): These bronchodilators relax the muscles surrounding the airways, improving airflow and reducing breathlessness. They are often used in combination with ICS. Long-acting Muscarinic Antagonists (LAMAs): These are another class of bronchodilators that work by blocking the action of muscarinic receptors in the airways, leading to relaxation and improved airflow. They are often used in combination with LABAs or ICS/LABAs. Combination ICS/LABA/LAMA Triple Therapy: Offering a comprehensive approach for severe COPD and asthma, combining the benefits of ICS, LABA, and LAMA for optimal symptom control.

Quick-Relief Medications: Used to rapidly alleviate acute symptoms like wheezing and shortness of breath. These are typically used as needed rather than on a daily basis. Short-acting Beta2-Agonists (SABAs): These bronchodilators provide rapid relief from bronchospasm, offering immediate symptom improvement. Anticholinergics: Similar to LAMAs, but used for quick relief, providing bronchodilation to address acute symptoms.

Biologics: Targeted therapies for specific subtypes of asthma and COPD, such as those driven by type 2 inflammation, offering a new level of personalized medicine. Recent developments include: April 2021: Hikma Pharmaceuticals PLC received US FDA approval for its product ADVAIR DISKUS in the US. This US FDA product approval strengthen company business in the US and boos the revenue growth in the US asthma and COPD drugs market., February 2022: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) offered a positive opinion commending approval for Sanofi’s Dupixent (dupilumab) as an add-on maintenance therapy to treat children of the age of 6 to 11 years with severe asthma with type 2 inflammation.. Potential restraints include: SIDE EFFECTS AND COMPLICATIONS DURING INHALATION 30, STRINGENT GOVERNMENT REGULATIONS 30. Notable trends are: Increasing prevalence and incidence rate of asthma and COPD boost the market growth..

A growing body of evidence has found that mortality rates are positively correlated with social inequalities, air pollution, elevated ambient temperature, availability of medical care and other factors. This study develops a model to predict the mortality rates for different diseases by county across the US. The model is applied to predict changes in mortality caused by changing environmental factors. A total of 3,110 counties in the US, excluding Alaska and Hawaii, were studied. A subset of 519 counties from the 3,110 counties was chosen by using systematic random sampling and these samples were used to validate the model. Step-wise and linear regression analyses were used to estimate the ability of environmental pollutants, socio-economic factors and other factors to explain variations in county-specific mortality rates for cardiovascular diseases, cancers, chronic obstructive pulmonary disease (COPD), all causes combined and lifespan across five population density groups. The estimated models fit adequately for all mortality outcomes for all population density groups and, adequately predicted risks for the 519 validation counties. This study suggests that, at local county levels, average ozone (0.07 ppm) is the most important environmental predictor of mortality. The analysis also illustrates the complex inter-relationships of multiple factors that influence mortality and lifespan, and suggests the need for a better understanding of the pathways through which these factors, mortality, and lifespan are related at the community level.

OR = Odds Ratio; CI = Confidence Interval; cpd = cigarettes per day; In addition to the variables in the table, model is also adjusted for coverage time on Medicare or Medicaid.*Center for Epidemiologic Studies Depression Scale-10 derived score. Score calculated only for participants responding to all 10 questions.†Number of comorbidities reported from among asthma, heart attack/coronary artery bypass surgery, diabetes and depression.A total of 862 individuals were missing covariates resulting in 26,065 individuals.Multivariable model of the association between participant characteristics and COPD among blacks and whites participating in the Southern Community Cohort Study (N = 26,065).

Subset of keywords used to generate estimates of respiratory illnesses.

According to DMI Analysis, Chronic Obstructive Pulmonary Disease Drugs Market reached US$ 24.67 billion in 2024 and is expected to reach US$ 35.15 billion by 2032